文献速递肺结节与肺癌

凡德他尼治疗既往经治RET重排晚期非小细胞肺癌(LURET):开放标签多中心2期试验

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2016-11-04

LURET是一项开放标签多中心2期试验,评估凡德他尼每日300mg口服治疗既往经治RET重排晚期非小细胞肺癌的疗效与安全性。主要终点独立评估客观缓解率在可评估患者中为53%(9/17,95%CI 28-77),达到主要终点;常见3/4级不良事件为高血压(58%)、皮疹(16%)、腹泻(11%)和QT延长(11%)。

要点

  • 凡德他尼在RET重排晚期NSCLC中显示抗肿瘤活性,客观缓解率达53%。
  • 常见3/4级不良事件包括高血压、皮疹、腹泻和QT延长,安全性可控。
  • RET重排可作为NSCLC靶向治疗的新分子亚组。

核心结论

  • 凡德他尼在晚期RET重排NSCLC患者中显示出临床抗肿瘤活性和可控的安全性。
  • 研究结果将RET重排定义为适合靶向治疗的非小细胞肺癌新分子亚组。

研究设计与样本

  • 开放标签、多中心、2期试验(LURET),患者每日口服凡德他尼300mg。
  • 通过约200家参与机构的全国基因组筛查网络筛选RET阳性患者。
  • 2013年2月7日至2015年3月19日期间,筛查1536例EGFR突变阴性NSCLC患者,34例(2%)为RET阳性,19例入组。
  • 主要终点为可评估患者的独立评估客观缓解率。

主要发现

  • 17例可评估患者中9例(53% [95%CI 28-77])达到客观缓解,满足主要终点。
  • 19例接受凡德他尼治疗的意向治疗人群中,9例(47% [95%CI 24-71])达到客观缓解。
  • 最常见的3或4级不良事件为高血压(11例 [58%])、腹泻(2例 [11%])、皮疹(3例 [16%])、皮肤干燥(1例 [5%])和QT延长(2例 [11%])。

关键数值与推荐

  • 主要终点客观缓解率在17例可评估患者中为53%(95%CI 28-77)。
  • 意向治疗人群客观缓解率为47%(95%CI 24-71)。

临床怎么用

  • 对于既往经治的RET重排晚期NSCLC患者,凡德他尼可作为靶向治疗选择之一。
  • 治疗期间需监测高血压、腹泻、皮疹、皮肤干燥和QT延长等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase inhibitor exhibiting RET kinase activity. We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. METHODS: In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. RET-positive patients were screened using a nationwide genomic screening network of about 200 participating institutions. Primary endpoint was the independently assessed objective response in eligible patients. This study is registered with UMIN-CTR, number UMIN000010095. FINDINGS: Between Feb 7, 2013, and March 19, 2015, 1536 patients with EGFR mutation-negative NSCLC were screened, of whom 34 were RET-positive (2%) and 19 were enrolled. Among 17 eligible patients included in primary analysis, nine (53% [95% CI 28-77]) achieved an objective response, which met the primary endpoint. In the intention-to-treat population of all 19 patients treated with vandetanib, nine (47% [95% CI 24-71]) achieved an objective response. At the data cutoff, median progression-free survival was 4·7 months (95% CI 2·8-8·5). The most common grade 3 or 4 adverse events were hypertension (11 [58%]), diarrhoea (two [11%]), rash (three [16%]), dry skin (one [5%]), and QT prolongation (two [11%]). INTERPRETATION: Vandetanib showed clinical antitumour activity and a manageable safety profile in patients with advanced RET-rearranged NSCLC. Our results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy. FUNDING: The Ministry of Health, Labour and Welfare of Japan and the Practical Research for Innovation Cancer Control from the Japan Agency for Medical Research and Development, AMED.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2016. PMID: 27825616. doi:10.1016/S2213-2600(16)30322-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。